Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

How I treat paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky

Blood (2021) 137 (10): 1304–1309.

https://doi.org/10.1182/blood.2019003812

Published: 2021

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

David J. Araten, MD, H. Leon Pachter, Robert J Dring, Elliot Newman, Steven M Cohen

Blood (2019) 134 (Supplement_1): 4795.

https://doi.org/10.1182/blood-2019-124571

Published: 2019

Journal Articles

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

Blood (2019) 134 (Supplement_1): 4913.

https://doi.org/10.1182/blood-2019-125343

Published: 2019

Journal Articles

Comparative Evaluation of Complement Factor D, C3, and C5 Inhibitors on Serum Bactericidal Activity Against Neisseria Meningitidis Isolates

Yongsen Zhao, Dharaben Patel, MS, Jane A Thanassi, BS, Mingjun Huang, PhD, Steven D Podos, PhD

Blood (2019) 134 (Supplement_1): 5763.

https://doi.org/10.1182/blood-2019-132253

Published: 2019

Journal Articles

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Jessica J Jalbert, PhD, Umesh Chaudhari, MD, Haixin Zhang, MSc, Jonathan Weyne, MD, Jamile M. Shammo, MD

Blood (2019) 134 (Supplement_1): 3407.

https://doi.org/10.1182/blood-2019-125867

Published: 2019

Journal Articles

Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients

Austin Kulasekararaj, MBBS MDMRCP FRCPath, Wynne Weston-Davies, Tadeusz Robak, MD, Miles Nunn, PhD, Agnieszka Piekarska, MD, Anna Szmigielska-Kaplon, MD, Anita Hill, MD PhD

Blood (2019) 134 (Supplement_1): 4797.

https://doi.org/10.1182/blood-2019-125263

Published: 2019

Journal Articles

Ravulizumab: a complementary option for PNH

Nathan T. Connell

Blood (2019) 133 (6): 503–504.

https://doi.org/10.1182/blood-2018-12-891499

Published: 2019

Journal Articles

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

Jong Wook Lee, Flore Sicre de Fontbrune, Lily Wong Lee Lee, Viviani Pessoa, Sandra Gualandro, Wolfgang Füreder, Vadim Ptushkin, Scott T. Rottinghaus, Lori Volles, Lori Shafner, Rasha Aguzzi, Rajendra Pradhan, Hubert Schrezenmeier, Anita Hill

Blood (2019) 133 (6): 530–539.

https://doi.org/10.1182/blood-2018-09-876136

Published: 2019

Includes: Supplemental data

Journal Articles

Platelets Promote Activation of the Complement System in Ovarian Cancer

Omayra Gonzalez Pagan, MD, Min Soon Cho, PhD, Vahid Afshar-Kharghan, MD

Blood (2018) 132 (Supplement 1): 4970.

https://doi.org/10.1182/blood-2018-99-116752

Published: 2018

Journal Articles

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Yasutaka Ueda, MD PhD, Hiroyuki Takamori, MD, Jun-Ho Jang, MD PhD, Chezi Ganzel, MD, Saskia Langemeijer, MD PhD, Makiko Osato, MS, Petra Muus, MD PhD, Jong-Wook Lee, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 2323.

https://doi.org/10.1182/blood-2018-99-111230

Published: 2018

Journal Articles

Complement-Mediated Thrombotic Microangiopathy: A Murky Presentation of a Rare Disease Entity

Patrick Fleming, MD, Maggie Cheung, MD, David Sokol, MD

Blood (2018) 132 (Supplement 1): 5005.

https://doi.org/10.1182/blood-2018-99-119893

Published: 2018

Journal Articles

Benefits and Limitations of Long-Term Eculizumab Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH): Real-World Data from Large Cohort Study in Russia

Aleksandr Kulagin, Olesya Klimova, Tatiana Rudakova, Irina Golubovskaya, Maria Ivanova, Anna Smirnova, Alexandra Lapina, Tatiana Bykova, Elena Babenko, Marina Popova, Vladimir Dobronravov, Boris Afanasyev

Blood (2018) 132 (Supplement 1): 2589.

https://doi.org/10.1182/blood-2018-99-120139

Published: 2018

Journal Articles

Thrombotic Microangiopathies Associated with Pregnancy: Diagnostic and Therapeutic Challenges

Maria Vinogradova, MD, Tatiana Kirsanova, MD, Roman Shmakov, MD PhD

Blood (2018) 132 (Supplement 1): 4810.

https://doi.org/10.1182/blood-2018-99-115220

Published: 2018

Journal Articles

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Regis Peffault De Latour, Jaroslaw P. Maciejewski, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Loree Larratt, MD FRCP(C), Ronald S. Go, MD, David Dingli, MD PhD, Amanda Wilson, PhD, Philippe Gustovic, MD, Aleksandr Kulagin

Blood (2018) 132 (Supplement 1): 1038.

https://doi.org/10.1182/blood-2018-99-111324

Published: 2018

Journal Articles

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Anita Hill, MD PhS, Scott T. Rottinghaus, MD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong-Wook Lee, MD PhD, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeffrey Szer, MBBS, Antonio M. Risitano, MD PhD, Shinji Nakao, MD PhD, Eric Bachman, Lori Shafner, PhD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Alexander Röth, MD, Regis Peffault De Latour

Blood (2018) 132 (Supplement 1): 625.

https://doi.org/10.1182/blood-2018-99-119147

Published: 2018

Journal Articles

Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies

Regis Peffault De Latour, Robert A. Brodsky, MD, Stephan Ortiz, RPh, PhD, Antonio M. Risitano, MD PhD, Jun-Ho Jang, MD PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Aleksandr Kulagin, Rajendra Pradhan, PhD, Scott T. Rottinghaus, MD, Rasha Aguzzi, MS, Richard A. Wells, MD DPhil, Jeffrey Szer, MBBS

Blood (2018) 132 (Supplement 1): 626.

https://doi.org/10.1182/blood-2018-99-110858

Published: 2018

Journal Articles

A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics

Ilene C. Weitz, MD, Aleksandr Kulagin, Shinji Nakao, MD PhD, Caroline I. Piatek, MD, Jeffrey Szer, MBBS, Scott T. Rottinghaus, MD, Lori Volles, MD, Andrew I. Damokosh, PhD, Rasha Aguzzi, MS, Loree Larratt, MD, Antonio M. Risitano, MD PhD

Blood (2018) 132 (Supplement 1): 627.

https://doi.org/10.1182/blood-2018-99-110623

Published: 2018

Journal Articles

Upregulation of CD38 Expression on Multiple Myeloma Cells By the HDAC Inhibitor Ricolinostat Augments the Efficacy of Daratumumab

Estefania Garcia-Guerrero, Sophia Danhof, Martin Schreder, MD, José A. Pérez-Simón, Hermann Einsele, Michael Hudecek

Blood (2017) 130 (Supplement 1): 1803.

https://doi.org/10.1182/blood.V130.Suppl_1.1803.1803

Published: 2017

Journal Articles

Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies

Alexander Roeth, MD, Scott T. Rottinghaus, MD, Anita Hill, MBChB (Hons), PhD, Jin Seok Kim, MD PhD, Hubert Schrezenmeier, MD, Louis Terriou, MD, Alvaro Urbano-Ispizua, MD, Richard A. Wells, MD DPhil, Jun Ho Jang, MD PhD, Jeff Szer, MB, BS, FRACP, Rasha Aguzzi, MS, Eric Scott Bachman, MD PhD, Andrew I. Damokosh, PhD, Lori Shafner, PhD, Jong-Wook Lee, MD

Blood (2017) 130 (Supplement 1): 3482.

https://doi.org/10.1182/blood.V130.Suppl_1.3482.3482

Published: 2017

NARROW

How I treat paroxysmal nocturnal hemoglobinuria

A complementary new drug for PNH

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

Plasmic and Plasic Αre Εxcellent Predictors of Severe ADAMTS13 Deficiency in Thrombotic Microangiopathy Patients without Secondary Causes

Comparative Evaluation of Complement Factor D, C3, and C5 Inhibitors on Serum Bactericidal Activity Against Neisseria Meningitidis Isolates

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients

Ravulizumab: a complementary option for PNH

Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

Platelets Promote Activation of the Complement System in Ovarian Cancer

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Complement-Mediated Thrombotic Microangiopathy: A Murky Presentation of a Rare Disease Entity

Benefits and Limitations of Long-Term Eculizumab Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH): Real-World Data from Large Cohort Study in Russia

Thrombotic Microangiopathies Associated with Pregnancy: Diagnostic and Therapeutic Challenges

Prognostic Value of Clone Size in Paroxysmal Nocturnal Hemoglobinuria (PNH) for Thrombotic Events in Untreated Patients in the International PNH Registry

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies

A Phase 3 Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitors: Results of a Subgroup Analysis with Patients Stratified By Baseline Hemolysis Level, Transfusion History, and Demographics

Upregulation of CD38 Expression on Multiple Myeloma Cells By the HDAC Inhibitor Ricolinostat Augments the Efficacy of Daratumumab

Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only